Actively Recruiting
Phase 2 Study Testing PETCT-Guided Treatment Pause in Metastatic Renal Cell Carcinoma Patients With Favorable or Intermediate IMDC Risk After PD-1PD-L1 and VEGFR-TKI Therapy
Led by Jinling Hospital, China · Updated on 2025-09-16
30
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new treatment strategy for patients with metastatic renal cell carcinoma RCC who have favorable or intermediate risk according to the International Metastatic RCC Database Consortium IMDC criteria. This phase 2 trial aims to test whether PETCT scans can safely guide pausing therapy after at least 12 months of first-line combination treatment with PD-1PD-L1 immune checkpoint inhibitors ICI and VEGFR tyrosine kinase inhibitors TKI. The study seeks to reduce continuous treatment burdens by using metabolic imaging to personalize therapy interruptions. Participants receive standard combination therapy of PD-1PD-L1 inhibitors and VEGFR-TKIs for at least 12 months. Those showing complete or partial metabolic response on PETCT scans within 24 months may stop treatment and enter a monitored therapy pause. During this break, patients undergo regular CT scans and PETCT if needed every 12 weeks. Treatment restarts if there are signs of disease progression based on tumor size or metabolic activity increases. Biological samples are collected throughout for future research. Participants are closely followed for up to 24 months to assess progression-free survival as the primary outcome. Secondary outcomes include response duration after therapy interruption, overall survival, safety, patient quality of life, anxiety and depression assessments, and cost-effectiveness. Patient-reported outcomes are collected using questionnaires like FKSI-19 and EORTC QLQ-C30. This trial pioneers the use of metabolic imaging to guide intermittent therapy in metastatic RCC, aiming to balance treatment benefits and reduce side effects and costs.
CONDITIONS
Brief Title
PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
Research Team
L
Le Qu, M.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here